Your search for issues in oncology matches 1842 pages
Showing 251 - 300
Incidence of Acute Kidney Injury in Patients Receiving Systemic Therapy for Cancer
In a Canadian population–based cohort study reported in the Journal of the National Cancer Institute, Kitchlu et al found that acute kidney injury (AKI) is common in patients receiving systemic therapy for newly diagnosed cancer and has increased in incidence in recent years. Study Details...
27% Drop in Overall U.S. Cancer Mortality Rate From 1991 to 2016
A steady 25-year decline has resulted in a 27% drop in the overall cancer death rate in the United States between 1991 and 2016. The data come from “Cancer Statistics, 2019,” the American Cancer Society’s annual report on cancer rates and trends. The report was published in CA: A...
Unplanned Hospitalizations in the Year After Cancer Diagnosis
In a California population–based cohort study reported in the Journal of Oncology Practice, Whitney et al found that 67% of hospitalizations in the year after cancer diagnosis were unplanned, with 67% of such hospitalizations originating in the emergency department. The study involved data...
Gleason 6 Score May Underestimate Prostate Cancer Mortality Risk in Black Men
Black men diagnosed with prostate cancer classified as low risk may actually have a more aggressive form of the disease that is more likely to be fatal than in nonblack men placed in the same prognostic category, according to results from a new study published as a research letter by Mahal et al in ...
2018 Young-Onset Colorectal Cancer Survey Report Covers Disease Stage at Diagnosis and More
Nearly three-quarters of patients with young-onset colorectal cancer are diagnosed with an advanced stage of the disease, a significantly higher percentage than has been reported for their more mature peers, according to a report from the Colorectal Cancer Alliance. The findings of...
Quality of Life and Patient- and Clinician-Reported Cumulative Toxicity
New research has found that quality of life for people with cancer is reduced by an accumulation of low-level toxicities just as much as it is from high-level adverse events. Additionally, patient-reported outcomes were more likely to reflect the impact on a patient’s physical well-being than ...
Regionalization of Surgery for Retroperitoneal Sarcoma Surgery to High-Volume Hospitals
In a study reported in the Journal of Oncology Practice, Villano et al found that regionalization of retroperitoneal sarcoma surgery—recognized as a complex cancer surgery—to high-volume hospitals has been slower than that observed for similarly complex pancreatic cancer surgery over...
New Study Examines Orphan Drug Exclusivity and Pricing
A new report commissioned by the National Organization for Rare Disorders (NORD) and published by the IQVIA Institute demonstrates that the 7-year market exclusivity granted to drugs designated under the Orphan Drug Act of 1983 for rare diseases is working as intended. In nearly every case, orphan...
Facing Death: Having the Difficult Conversation With Your Patients
Michael Becker, a former CEO for two biotechnology companies, discusses his terminal head and neck cancer diagnosis and his message for oncologists: be proactive and, at the appropriate time, talk with your patients about death and dying. For more information about Michael Becker’s blog and his HPV vaccine advocacy, visit mdbcancerjourney.com. To read about Michael Becker's advocacy efforts to increase vaccination rates for human papillomavirus-related cancers, see his Patient's Corner column "HPV-Related Cancers Like Mine Are Avoidable, So Why Aren't More Kids Being Vaccinated?" published in the May 10, 2018 issue of The ASCO Post.
Association Between Systemic Lupus Erythematosus and Cancer Risk
New research published by Song et al in Arthritis Research & Therapy evaluated the link between lupus and cancer risk, supporting the data from earlier studies. The newer study indicates an association between systemic lupus erythematosus (SLE) and increased risk for several cancers (blood,...
Increased Risk for Breast Cancer After Childbirth May Last More Than 2 Decades
Although parity—time since most recent birth— is recognized as a protective factor against breast cancer, an analysis of data from 15 prospective cohort studies to assess breast cancer risk in relation to recent childbirth has found that compared to women of the same age who had never...
ASCO and ESMO Publish Joint Assessment of Their Value Frameworks
To better understand the performance characteristics of ASCO’s Value Framework Net Health Benefit Score version 2 (ASCO-NHB v2) and the European Society for Medical Oncology’s (ESMO’s) Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1), ASCO and ESMO undertook a...
Does Tailored Lifestyle Feedback Given During Colorectal Cancer Screening Improve Disease-Preventive Behaviors?
A program that provided individually tailored lifestyle recommendations for patients undergoing screening for colorectal cancer helped encourage healthy behavior, according to results published by Knudsen et al in Cancer Epidemiology, Biomarkers & Prevention. “It is well known that...
Apixaban Thromboprophylaxis in Patients With Cancer
In the Canadian phase III AVERT trial reported in The New England Journal of Medicine, Carrier et al found that the oral factor Xa inhibitor apixaban reduced the risk of venous thromboembolism vs placebo among intermediate- to high-risk ambulatory patients with cancer starting chemotherapy but was...
Reducing Infections in Patients With AML Receiving Induction and Reinduction Chemotherapy
In a report in the Journal of Oncology Practice, Morris et al described an initiative that has been successful in reducing the incidence of invasive fungal infections in patients with acute myeloid leukemia (AML) receiving induction and reinduction therapy at the University of Virginia Health...
Vitamin D Supplementation and Cancer Risk
In a trial reported in The New England Journal of Medicine by Manson et al, vitamin D supplementation was found to have no benefit in reducing risk of invasive cancer vs placebo over 5 years of follow-up. Study Details The trial was a randomized, placebo-controlled trial, with a two-by-two...
ASCO and Friends of Cancer Research Applaud NCI’s Expansion of Clinical Trial Eligibility Criteria
ASCO and Friends of Cancer Research (Friends) applaud the National Cancer Institute's (NCI) recent revision of its clinical trial protocol template to broaden eligibility criteria for cancer clinical trials. The protocol template was expanded to help increase the opportunity for ...
FDA Pipeline: New Priority Reviews, Designations, and Clearances, Plus Statements on Genetic Testing and Class Labeling
The U.S. Food and Drug Administration (FDA) recently issued the following new approvals and designations: Priority Review for Atezolizumab in Combination With Chemotherapy for the Initial Treatment of Extensive-Stage SCLC The FDA accepted a supplemental biologics license application...
Reshma Jagsi, MD, DPhil, and Rachel A. Freedman, MD, MPH, on Over- and Undertreatment: Getting It Right
Reshma Jagsi, MD, DPhil, of the University of Michigan, and Rachel A. Freedman, MD, MPH, of Dana-Farber Cancer Institute, discuss the twin challenges of overtreating people with cancer and the missed opportunities and dangers of undertreatment.
Kathy S. Albain, MD, on Breast Cancer, Ethnicity, and Clinical Outcomes: Results From the TAILORx Trial
Kathy S. Albain, MD, of Loyola University Stritch School of Medicine, discusses study findings on race, ethnicity, and patient outcomes in hormone receptor–positive, HER2-negative, node-negative breast cancer (Abstract GS4-07).
Roberto A. Leon-Ferre, MD, on Decreasing Hot Flashes: Results From an ACCRU Trial
Roberto A. Leon-Ferre, MD, of the Mayo Clinic, discusses study findings on the effectiveness of oxybutynin in decreasing the frequency and severity of hot flashes (Abstract GS6-01).
Laura S. Dominici, MD, on Young Women With Breast Cancer: Local Therapy and Quality of Life
Laura S. Dominici, MD, of the Dana-Farber Cancer Institute, discusses the lower quality-of-life scores seen after unilateral or bilateral mastectomy compared with breast-conserving surgery in women younger than age 40 who are treated for breast cancer (Abstract GS6-05).
Shoshana M. Rosenberg, ScD, on Quality of Life and the Impact of Breast Cancer Surgery
Shoshana M. Rosenberg, ScD, of Dana-Farber Cancer Institute, discusses her study findings on the lower quality of life associated with mastectomy, and the need for intervention and timely referrals to supportive resources, especially for underserved populations (Abstract GS6-04).
SABCS 2018: Surgical Choice May Impact Long-Term Quality of Life in Young Adults With Breast Cancer
A study by Dominici et al investigated the long-term quality of life outcomes in young breast cancer survivors across three surgical strategies: breast-conserving surgery, unilateral mastectomy, and bilateral mastectomy. The researchers found that patients who underwent mastectomy had lower breast...
Alok A. Khorana, MD, on Reducing VTE Associated With Systemic Cancer Therapy: Results From the CASSINI Trial
Alok A. Khorana, MD, of the Cleveland Clinic, discusses study findings on rivaroxaban thromboprophylaxis in high-risk ambulatory patients, which showed a reduction in venous thromboembolism and related death (Abstract LBA1).
Factors Affecting Use of Outpatient Specialty Palliative Care Clinics Among Patients With Advanced Cancer
In a study reported in the Journal of Oncology Practice, Yu et al identified factors affecting use of outpatient specialty palliative care (OSPC) among patients with advanced cancer in the University of Pittsburgh Medical Center Hillman Cancer Center Network (UPMC-HCCN). Study Details The...
Norman E. Sharpless, MD: Director of the National Cancer Institute: Articulating a Vision
Norman E. Sharpless, MD, Director of the National Cancer Institute, discusses his vision for the NCI in four key areas––big data, clinical trials, workforce development, and basic science––and how this vision affects the hematology community.
Marine Omega-3 Fatty Acid Supplementation and Cancer Risk
In a trial reported in The New England Journal of Medicine by Manson et al, marine n-3 (omega-3) fatty acid supplementation was found to have no benefit in reducing the risk for invasive cancer vs placebo over 5 years of follow-up. Higher intake of n-3 fatty acids has been associated with a reduced ...
Many Patients Do Not Receive Surveillance Colonoscopies Following a Diagnosis of High-Risk Adenomas
A population-based study examining patient receipt of a surveillance colonoscopy 3 years after the removal of high-risk adeonomatous polyps has found that the procedure was underutilized and varied by health-care system, patient age, and number of adenomas found. Strategies to improve adherence to...
Dissemination of Misleading Information on Prostate Cancer on Social Media
YouTube videos on prostate cancer often offer misleading or biased medical information that poses potential health risks to patients, an analysis of the social media platform published by Loeb et al in European Urology showed. For the latest analysis, researchers, which included social...
2018 National Youth Tobacco Survey Shows Increase in E-Cigarette Use Among Youth
The U.S. Food and Drug Administration (FDA) and U.S. Centers for Disease Control and Prevention (CDC) recently released new findings from the National Youth Tobacco Survey (NYTS) showing that more than 3.6 million middle and high school students were current (past 30 day) e-cigarette users in...
Cardiovascular Toxicities Associated With Immune Checkpoint Inhibitor Treatment
In a pharmacovigilance study reported in The Lancet Oncology, Salem et al found that immune checkpoint inhibitors can cause “severe and disabling inflammatory cardiovascular immune-related adverse events” that need to be considered in patient care and clinical trial design. Study...
Discontinuation of Follow-up Care Among Women With Early-Stage Breast Cancer
In a study using linked Surveillance, Epidemiology, and End Results (SEER)-Medicare data reported in the Journal of Oncology Practice, Quyyumi et al found that 21% of women with early-stage breast cancer discontinued follow-up care within 5 years after diagnosis. Study Details The study involved...
Undertreatment of High-Risk Prostate Cancer in Latino Men
New research by Lichtensztajn et al in JNCCN—Journal of the National Comprehensive Cancer Network examined disparities in care for Latino men with prostate cancer. A team of researchers from UCSF Helen Diller Family Comprehensive Cancer Center, Stanford Cancer Institute, and...
Nosayaba Osazuwa-Peters, MPH, PhD, on Suicide Among Male Patients With Cancer: Study Findings
Nosayaba Osazuwa-Peters, MPH, PhD, of St. Louis University, discusses study findings on married cancer survivors with advanced stage disease who were less likely to die by suicide, highlighting the value of supportive care in cancer survivorship (Abstract 181).
Allison S. Betof Warner, MD, PhD, on Managing Immune-Related Adverse Events: Incorporating Guidelines
Allison S. Betof Warner, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the rationale for immunotherapy and combination treatments, identifying the agents that lead to toxicities, and ways to manage them.
Charles von Gunten, MD, PhD, on Protecting Opioid Access for Patients in Need
Charles von Gunten, MD, PhD, of OhioHealth, discusses the critical need for opioids to manage cancer pain as well as the myth of addiction, which may impede best care.
Mary E. Johnson on Holding Vigil With Dying Loved Ones
Mary E. Johnson, author of Stay With Me Awhile, discusses her play, a compilation of vigil stories from across cultures and religions, and the profound impact the performances have had on audience members.
Betty R. Ferrell, PhD, on Quality of Life in the Era of Immunotherapy
Betty R. Ferrell, PhD, of City of Hope, discusses the many advances in immunotherapy and the drugs’ effect on patients’ quality of life, including psychological well-being.
ACS Report Looks at Ways to Improve Outcomes for Cancer Survivors and Caregivers
Growing numbers of cancer survivors, provider shortages, rising health-care costs, and socioeconomic disparities in health outcomes have created an urgent need to provide coordinated, comprehensive, personalized care for cancer survivors. A new report from the American Cancer Society (ACS) creates...
Adverse Mental Health Outcomes in Breast Cancer Survivors
In a systematic review of the literature reported in the Journal of the National Cancer Institute, Carreira et al found that most evidence strongly supports increased risk of anxiety, depression, neurocognitive dysfunction, and other forms of psychological issues in survivors of breast...
Financial Toxicity Experienced by Adults With Cancer
In a study reported in the Journal of Oncology Practice, Knight et al found that 26% of patients with cancer acknowledged ‘financial toxicity’—treatment-related financial harm—with respect to cancer care, and that this toxicity was associated with consequences such as...
2018 Palliative Care: Can an AI-Based App Help Manage Cancer-Related Pain?
A study of 112 patients with metastatic solid tumors found that the use of an artificial intelligence (AI)-based smartphone app reduced both the severity of patients’ reported pain and hospital admissions. After an 8-week period, patients who used the AI-powered app to monitor and address...
2018 Palliative Care: Immunotherapy-Related Adverse Events May Be More Common Than Initially Reported
An analysis of nearly 2,800 patients with non­–small cell lung cancer (NSCLC) who received the immune checkpoint inhibitors nivolumab (Opdivo), pembrolizumab (Keytruda), or atezolizumab (Tecentriq) found that adverse events may be more common than reported in the initial trials that led...
Effect of Early Cardiotoxicity on Outcomes in Pediatric AML
In an analysis from the Children’s Oncology Group AAML0531 trial reported in the Journal of Clinical Oncology, Getz et al found that early treatment-related cardiotoxicity may be associated with poorer event-free and overall survival in pediatric acute myeloid leukemia (AML). Study Details...
Progression-Free Survival and Health-Related Quality of Life in Randomized Clinical Trials
A review and analysis of randomized clinical trials published by Kovic et al in JAMA Internal Medicine questioned whether interventions that prolong progression-free survival (PFS) in patients with cancer improve their health-related quality of life (HRQoL). The systematic review and quantitative...
ASCO Submits Comment Letters to the FDA on Modernizing Clinical Trials
ASCO recently submitted two comment letters from ASCO President Monica M. Bertagnolli, MD, FACS, FASCO, to the U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb, MD, related to the modernization of clinical trials. The first letter provided the FDA with comments on...
Findings From the National Cancer Opinion Survey: Alternative Therapies, Cost of Care, and More
Nearly 4 in 10 Americans believe cancer can be cured solely through alternative therapies, according to ASCO's second annual National Cancer Opinion Survey. This is despite research showing that patients who use alternative therapies instead of standard cancer treatments have much higher...
The COLORS Training: Online LGBT Cultural Competency for Oncologists
An interactive online LGBT cultural competency training program for oncologists may be acceptable and feasible—and may improve LGBT-related knowledge and clinical practices, according to preliminary results of a pilot study of oncologists in Florida presented by Schlumbrecht et al at...
Prognostic Risk Model for African American Women With Breast Cancer
A prognostic model developed using a machine learning approach may be able to identify African American patients with breast cancer who have an increased risk of death, according to results of a study presented by Bhattarai et al at the 11th AACR Conference on The Science of Cancer Health...
